Cover Image
市場調查報告書

Hospira, Inc.的產品平台分析

Hospira, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 240925
出版日期 內容資訊 英文 39 Pages
訂單完成後即時交付
價格
Back to Top
Hospira, Inc.的產品平台分析 Hospira, Inc. - Product Pipeline Review - 2015
出版日期: 2015年08月31日 內容資訊: 英文 39 Pages
簡介

本報告提供Hospira, Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,給藥途徑,分子類型,各作用機制的治療藥評估,最近的開發平台趨勢,暫停中的計劃等相關資訊。

Hospira, Inc.的基本資料

  • 概要
  • 主要資訊
  • 企業資料

Hospira, Inc.:R&D概要

  • 主要的治療範圍

Hospira, Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 合作夥伴產品
    • 合作夥伴產品/聯合治療模式

Hospira, Inc.:開發中產品概況

  • 後期開發中產品
    • 登記前的產品/聯合治療模式
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第一階段的產品/聯合治療模式
  • 初期階段的開發中產品
    • 藥物研發中的產品/聯合治療模式

Hospira, Inc.:藥物簡介

  • epoetin zeta
  • filgrastim
  • pegfilgrastim
  • rituximab biosimilar
  • bevacizumab biosimilar

Hospira, Inc.:開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Hospira, Inc.:最近的開發平台趨勢

Hospira, Inc.:暫停中的計劃

Hospira, Inc.:開發中止的開發中產品

  • 開發中止的開發中產品簡介
  • E-21R

Hospira, Inc.:企業發表

Hospira, Inc.:總公司和子公司的所在地

Hospira, Inc.:主要製造設備

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07374CDB

Summary

Global Markets Direct's, 'Hospira, Inc. - Product Pipeline Review - 2015', provides an overview of the Hospira, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Hospira, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Hospira, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Hospira, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Hospira, Inc.'s pipeline products

Reasons to buy

  • Evaluate Hospira, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Hospira, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Hospira, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Hospira, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Hospira, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Hospira, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Hospira, Inc. Snapshot
    • Hospira, Inc. Overview
    • Key Information
    • Key Facts
  • Hospira, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Hospira, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
  • Hospira, Inc. - Pipeline Products Glance
    • Hospira, Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Hospira, Inc. - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Hospira, Inc. - Early Stage Pipeline Products
      • Discovery Products/Combination Treatment Modalities
  • Hospira, Inc. - Drug Profiles
    • epoetin zeta
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • filgrastim
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • pegfilgrastim
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • rituximab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • bevacizumab biosimilar
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Hospira, Inc. - Pipeline Analysis
    • Hospira, Inc. - Pipeline Products by Target
    • Hospira, Inc. - Pipeline Products by Route of Administration
    • Hospira, Inc. - Pipeline Products by Molecule Type
    • Hospira, Inc. - Pipeline Products by Mechanism of Action
  • Hospira, Inc. - Recent Pipeline Updates
  • Hospira, Inc. - Dormant Projects
  • Hospira, Inc. - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • E-21R
  • Hospira, Inc. - Company Statement
  • Hospira, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Hospira, Inc. - Key Manufacturing Facilities
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Hospira, Inc., Key Information
  • Hospira, Inc., Key Facts
  • Hospira, Inc. - Pipeline by Indication, 2015
  • Hospira, Inc. - Pipeline by Stage of Development, 2015
  • Hospira, Inc. - Monotherapy Products in Pipeline, 2015
  • Hospira, Inc. - Partnered Products in Pipeline, 2015
  • Hospira, Inc. - Partnered Products/ Combination Treatment Modalities, 2015
  • Hospira, Inc. - Pre-Registration, 2015
  • Hospira, Inc. - Phase III, 2015
  • Hospira, Inc. - Phase I, 2015
  • Hospira, Inc. - Discovery, 2015
  • Hospira, Inc. - Pipeline by Target, 2015
  • Hospira, Inc. - Pipeline by Route of Administration, 2015
  • Hospira, Inc. - Pipeline by Molecule Type, 2015
  • Hospira, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Hospira, Inc. - Recent Pipeline Updates, 2015
  • Hospira, Inc. - Dormant Developmental Projects,2015
  • Hospira, Inc. - Discontinued Pipeline Products, 2015
  • Hospira, Inc., Other Locations
  • Hospira, Inc., Subsidiaries
  • Hospira, Inc., Key Manufacturing Facilities

List of Figures

  • Hospira, Inc. - Pipeline by Top 10 Indication, 2015
  • Hospira, Inc. - Pipeline by Stage of Development, 2015
  • Hospira, Inc. - Monotherapy Products in Pipeline, 2015
  • Hospira, Inc. - Partnered Products in Pipeline, 2015
  • Hospira, Inc. - Pipeline by Top 10 Target, 2015
  • Hospira, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Hospira, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Hospira, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top